JP2023535792A - コロナウイルス治療のための抗ｃｄ３抗体 - Google Patents

コロナウイルス治療のための抗ｃｄ３抗体 Download PDF

Info

Publication number
JP2023535792A
JP2023535792A JP2023505756A JP2023505756A JP2023535792A JP 2023535792 A JP2023535792 A JP 2023535792A JP 2023505756 A JP2023505756 A JP 2023505756A JP 2023505756 A JP2023505756 A JP 2023505756A JP 2023535792 A JP2023535792 A JP 2023535792A
Authority
JP
Japan
Prior art keywords
antibody
subject
amino acid
acid sequence
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535792A5 (https=
Inventor
シャイルバイ クンワー
エル．ウェイナー ハワード
Original Assignee
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー filed Critical ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー
Publication of JP2023535792A publication Critical patent/JP2023535792A/ja
Publication of JP2023535792A5 publication Critical patent/JP2023535792A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023505756A 2020-07-30 2021-07-30 コロナウイルス治療のための抗ｃｄ３抗体 Pending JP2023535792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058978P 2020-07-30 2020-07-30
US63/058,978 2020-07-30
PCT/EP2021/071491 WO2022023566A2 (en) 2020-07-30 2021-07-30 Cd-3 antibodies for the treatment of coronavirus

Publications (2)

Publication Number Publication Date
JP2023535792A true JP2023535792A (ja) 2023-08-21
JP2023535792A5 JP2023535792A5 (https=) 2024-08-05

Family

ID=77543470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505756A Pending JP2023535792A (ja) 2020-07-30 2021-07-30 コロナウイルス治療のための抗ｃｄ３抗体

Country Status (8)

Country Link
US (1) US20230227555A1 (https=)
EP (1) EP4188440A2 (https=)
JP (1) JP2023535792A (https=)
CN (1) CN116406274B (https=)
AU (1) AU2021316723A1 (https=)
CA (1) CA3185105A1 (https=)
IL (1) IL299744A (https=)
WO (1) WO2022023566A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220332822A1 (en) * 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
WO2023218100A1 (en) * 2022-05-13 2023-11-16 Tiziana Life Sciences Plc Nasal formulations of foralumab

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526627A (ja) * 2016-08-29 2019-09-19 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 抗−ｃｄ３抗体製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654210A (en) 1979-04-26 1987-03-31 Ortho Pharmaceutical Corporation Methods and compositions using complement fixing monoclonal antibody to human T cells
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
WO1991006319A1 (en) 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US7883703B2 (en) * 2003-11-14 2011-02-08 The Brigham And Women's Hospital, Inc. Methods of modulating immunity
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
MX2008014710A (es) * 2006-05-19 2009-02-12 Amgen Inc Anticuerpos para coronavirus del sars.
AU2014319921A1 (en) * 2013-09-11 2016-03-17 Compugen Ltd. Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis
EP3634478A4 (en) * 2017-06-06 2021-03-24 The Brigham and Women's Hospital, Inc. METHOD OF SUPPRESSION OF MICROGLIA ACTIVATION
IL296276A (en) * 2020-03-10 2022-11-01 Tiziana Life Sciences Plc Compositions of il-6/il-6r antibodies and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526627A (ja) * 2016-08-29 2019-09-19 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 抗−ｃｄ３抗体製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TUGOLBAI TAGAEV; ET AL: "POTENTIAL EFFECTS OF ADJUVANT TREATMENTS ON CORONAVIRUS DISEASE 2019 (COVID-19)", JOURNAL OF COMMUNICABLE DISEASES, vol. 52, no. 2, JPN5024002240, 9 July 2020 (2020-07-09), pages 46 - 49, ISSN: 0005781496 *
VISHNU PRIYAN: "TIZIANA’S FORALUMAB SUPPRESSES LUNG INFLAMMATION IN BRAZIL COVID-19 TRIAL", PHARMACEUTICAL TECHNOLOGY, JPN5024002241, 3 February 2021 (2021-02-03), pages 1 - 3, ISSN: 0005781495 *

Also Published As

Publication number Publication date
WO2022023566A2 (en) 2022-02-03
US20230227555A1 (en) 2023-07-20
AU2021316723A1 (en) 2023-01-19
CN116406274B (zh) 2026-02-17
IL299744A (en) 2023-03-01
CA3185105A1 (en) 2022-02-03
CN116406274A (zh) 2023-07-07
WO2022023566A3 (en) 2022-03-10
EP4188440A2 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
US20230039028A1 (en) Methods of suppressing microglial activation
JP7375252B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
JP2022512709A (ja) 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
CN119215164A (zh) 用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂
JP2023535792A (ja) コロナウイルス治療のための抗ｃｄ３抗体
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
AU2004275860A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
AU2018228246A1 (en) Preventive or therapeutic agent for HTLV-1-associated myelopathy using low-dose anti-CCR4 antibody
JP2022553703A5 (https=)
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
US20230190804A1 (en) Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
WO2024146630A1 (zh) 一种tslp抗体治疗哮喘的方法
CN121909045A (zh) 一种重组抗IL-23p19抗体治疗中重度银屑病的方法
CN114746444A (zh) 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260127